Search

An adolescent boy exhibited lack of efficacy during treatment with risperidone for psychotic symptoms. At the age of 17, he developed diabetic ketoacidosis during treatment with olanzapine for psychotic symptoms. The boy had been receiving treatment for about 6 years in a child and adolescent psychiatry outpatient clinic. He initially received risperidone with no benefit, then switched to aripiprazole with improvement. However, after starting olanzapine, he experienced symptoms of diabetic ketoacidosis and was diagnosed with olanzapine-induced diabetic ketoacidosis. Treatment with olanzapine was discontinued and he was discharged with insulin therapy. [Extracted from the article]

A 61-year-old woman with a history of major paranoid psychosis and asthma developed a recurrence of severe acute respiratory distress syndrome while being treated with risperidone. Between October 2015 and June 2016, she experienced 19 episodes of acute respiratory decompensation, some of which required emergency and intensive care unit transfers. The ICU physician refused further transfer due to the high frequency of recurrence and difficulty with extubation. The recurrence of respiratory distress syndrome was considered to be a result of the risperidone treatment. After stopping the medication, the woman's respiratory status improved dramatically and the syndrome resolved. [Extracted from the article]

A 34-year-old man experienced drug ineffectiveness while being treated with pipamperone, risperidone, and valproate for behavioral control. The man had recurrent behavioral problems including aggression and self-injuries, as well as obstipation. He was diagnosed with autism based on his symptoms and had a history of epileptic seizures. Despite starting treatment with the aforementioned medications, they were not effective in controlling his behaviors. [Extracted from the article]

A 32-year-old man experienced neuroleptic malignant syndrome (NMS) while being treated with lithium for bipolar disorder and risperidone for manic decompensation. The man had a medical history of bipolar disorder and was already taking lithium, as well as receiving treatment for tonsillitis and manic decompensation. After 72 hours of starting risperidone, he developed symptoms including autonomic dysfunction, altered mental status, fever, and muscular rigidity. The man received life support measures and risperidone treatment was discontinued. It was determined that the NMS was likely caused by the combination of lithium and risperidone. [Extracted from the article]

This article from Reactions Weekly discusses two case reports of patients who experienced hyperhidrosis (excessive sweating) during treatment with aripiprazole for obsessive-compulsive disorder and multiple motor tics. The first case involves a 38-year-old woman with a history of various medical conditions who developed hyperhidrosis after starting aripiprazole. The second case involves a 17-year-old boy who did not respond to risperidone for his tics but experienced hyperhidrosis when treated with aripiprazole. In both cases, the hyperhidrosis resolved when aripiprazole was discontinued but recurred when it was re-initiated. [Extracted from the article]

A 55-year-old man developed venous thromboembolism (VTE) and pulmonary embolism while being treated for paranoid schizophrenia with ziprasidone, amisulpride, and risperidone. He experienced sedation and weight gain as side effects of amisulpride and risperidone, leading to a switch in his medication to ziprasidone. However, he was later hospitalized with breathlessness and diagnosed with pulmonary embolism and VTE, which were considered to be caused by ziprasidone. Treatment with acenocoumarol and support stockings was planned. [Extracted from the article]

A 61-year-old woman with a history of major paranoid psychosis and asthma developed severe acute respiratory distress syndrome (ARDS) while being treated with risperidone. Between October 2015 and June 2016, she experienced 19 episodes of acute respiratory decompensation, some of which required emergency and intensive care unit transfers. The recurrence of ARDS was attributed to risperidone, and her treatment with the medication was discontinued. After stopping the medication, her respiratory status improved dramatically, and the ARDS resolved. [Extracted from the article]

A 34-year-old man experienced drug ineffectiveness while being treated with pipamperone, risperidone, and valproate for behavioral control. The man had recurrent behavioral problems including aggression and self-injuries, as well as obstipation. He was diagnosed with autism based on his symptoms and had a history of epileptic seizures. Despite starting treatment with the aforementioned medications, they were not effective in controlling his behaviors. [Extracted from the article]

A 32-year-old man experienced neuroleptic malignant syndrome (NMS) while being treated with lithium for bipolar disorder and risperidone for manic decompensation. The man had a medical history of bipolar disorder and was already taking lithium, as well as receiving treatment for tonsillitis and manic decompensation. After 72 hours of starting risperidone, he developed symptoms including autonomic dysfunction, altered mental status, fever, and muscular rigidity. The man received life support measures and risperidone treatment was discontinued. It was determined that he developed NMS as a result of the combination of lithium and risperidone. [Extracted from the article]

This article discusses two case reports of patients who developed hyperhidrosis (excessive sweating) during treatment with aripiprazole for obsessive-compulsive disorder and multiple motor tics. The first case involves a 38-year-old woman with a history of various medical conditions who experienced hyperhidrosis after starting aripiprazole. The second case involves a 17-year-old boy who had no therapeutic response to risperidone for his motor tics, but experienced hyperhidrosis when treated with aripiprazole. In both cases, the hyperhidrosis resolved when aripiprazole was discontinued, but recurred when the medication was re-initiated. [Extracted from the article]

A 55-year-old man developed venous thromboembolism (VTE) and pulmonary embolism while being treated for paranoid schizophrenia with ziprasidone, amisulpride, and risperidone. He initially experienced sedation and weight gain from amisulpride and risperidone, so his treatment was switched to ziprasidone. However, he was later hospitalized with breathlessness and diagnosed with pulmonary embolism and VTE, which were considered to be secondary to ziprasidone. Treatment with acenocoumarol and support stockings was planned. [Extracted from the article]

A 44-year-old woman developed drug-induced hepatotoxicity while being treated with risperidone for schizophrenia. The woman had a history of substance abuse, including alcohol, marijuana, and cocaine, which had ceased prior to her hospitalization. She was admitted to a psychiatric unit due to an exacerbation of her mental illness and was started on risperidone. However, she experienced symptoms of exhaustion, nausea, abdominal pain, and malaise, and her blood analysis showed elevated liver enzyme levels. The diagnosis of drug-induced hepatotoxicity was made, and her symptoms improved and resolved with treatment. She was subsequently started on a different antipsychotic medication. [Extracted from the article]

In a retrospective study involving 387 patients, 12 patients were described who experienced various toxicities while being treated with risperidone or paliperidone. The toxicities included weight gain, hyperprolactinaemia, headaches, and nausea or vomiting. The patients received either risperidone or paliperidone, and some of them had to discontinue the treatment due to weight gain. The study did not provide specific information about the patients' ages, sexes, dosages, routes of administration, therapeutic indications, durations of treatment, or outcomes. [Extracted from the article]

A female patient with intellectual disability and unspecified psychosis developed tardive dyskinesia while being treated with risperidone and lamotrigine. The patient continued to take these medications for several years and later developed severe atlantoaxial subluxation and spinal cord depression. She is currently awaiting neurological surgery for occipital cervical fusion and decompression surgery. [Extracted from the article]

A 63-year-old man with a history of Creutzfeldt-Jakob disease (CJD) experienced worsening of extrapyramidal symptoms while being treated with risperidone and haloperidol for agitation. The man was admitted for encephalopathy and underwent tests to determine whether he had CJD or autoimmune encephalitis. During his hospital stay, he received haloperidol and risperidone for agitation, which led to increased dysphagia and tremor. His medication was changed to olanzapine and quetiapine, resulting in better management of his symptoms. A week later, his CSF analysis confirmed a diagnosis of CJD. It was concluded that the exacerbation of extrapyramidal symptoms was due to the therapy with haloperidol and risperidone. [Extracted from the article]

A 16-year-old girl with neuropsychiatric lupus experienced recurrent episodes of angioedema and pancreatitis while being treated with lisinopril and risperidone. She also had a lack of efficacy with aripiprazole. The girl presented with symptoms such as fatigue, pain, fevers, and decreased appetite, and was diagnosed with systemic lupus erythematous (SLE) and various complications. She received treatment with different medications, but experienced adverse reactions. Eventually, her symptoms improved with the use of benztropine and olanzapine. [Extracted from the article]

A 15-year-old boy with catatonic schizophrenia experienced a lack of efficacy during treatment with risperidone. He had a family history of possible psychotic disorder and anxiety disorder. After non-adherence to lurasidone and trazodone, he was admitted and started on risperidone, but his symptoms worsened. He was then switched to quetiapine and clonazepam, and later received lorazepam. Eventually, he was transitioned to haloperidol decanoate and discharged, but experienced another psychotic decompensation and was rehospitalized. [Extracted from the article]

A 9-year-old boy with autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) experienced drug toxicity after accidentally ingesting a high dose of risperidone. He presented with symptoms such as conscious lethargy, nasal bleeding, dysphagia, increased pulse rate, increased blood pressure, increased respiratory rate, cogwheel rigidity, and dystonic contractions. Despite treatment with diazepam, his symptoms persisted, but they resolved after treatment with biperiden. The boy was monitored in the ICU for 24 hours and then followed up in the pediatric ward for 48 hours before being discharged. [Extracted from the article]

A 56-year-old man developed neuroleptic malignant syndrome (NMS) after taking risperidone for bipolar affective disorder. He presented to the emergency department with altered consciousness, fatigue, high fever, and slowing movements. Physical evaluation revealed somnolence, confusion, rigidity of all four limbs, and short incoherent responses to sound. Laboratory tests showed elevated creatine kinase, thrombocytopenia, and lymphopenia. The man was diagnosed with NMS based on specific criteria and was also found to have COVID-19. Treatment included discontinuing risperidone and providing supportive therapy, antibiotics, and mechanical ventilation. The man eventually improved and was discharged. [Extracted from the article]

In a case study conducted between March 2019 and March 2023, three patients developed hyperprolactinaemia while being treated with levosulpiride or risperidone. One patient had elevated prolactin levels attributed to risperidone, while the other two patients had elevated prolactin levels attributed to both levosulpiride and risperidone. The study does not provide specific information about the patients' ages, sexes, dosages, routes of administration, indications for treatment, outcomes, or durations of treatment to reaction onsets. [Extracted from the article]

A 19-year-old woman with schizophrenia experienced oculogyric crisis after taking aripiprazole and risperidone concurrently. She then discontinued the medication on her own, which was considered drug misuse. The woman's symptoms were partially relieved with trihexyphenidyl, but they recurred. After switching to paliperidone and increasing the risperidone dose, her symptoms persisted. Eventually, she was switched to clozapine, which effectively controlled her symptoms. The oculogyric crisis was attributed to the drug interaction between aripiprazole and risperidone. [Extracted from the article]

A 36-year-old woman experienced various toxicities while being treated for attention deficit/hyperactivity disorder (ADHD), depression, anxiety attacks, and acute stress disorder. She developed bradycardia (slow heart rate) during treatment with guanfacine, and her bradycardia was masked by aripiprazole and risperidone. She also exhibited lack of efficacy to risperidone for anxiety attacks and developed depression as a side effect of risperidone. After discontinuing guanfacine, her heart rate recovered. The relationship between bradycardia and guanfacine was confirmed by a drug reaction probability score. [Extracted from the article]

A 61-year-old woman experienced hypothermia and thrombocytopenia while being treated with risperidone for schizoaffective disorder. Initially, her hypothermia was attributed to prolonged exposure to cold temperatures, but further investigation revealed that it was likely a side effect of the risperidone. The woman's risperidone treatment was discontinued, and she was switched to quetiapine, which resulted in the resolution of her hypothermia and thrombocytopenia. [Extracted from the article]

A 40-year-old woman developed hyperprolactinaemia while being treated with risperidone for paranoid schizophrenia. She experienced symptoms such as irritability, low mood, social withdrawal, aggression, and hallucinations. Her risperidone dose was gradually increased to 8 mg/day, but she developed galactorrhea and missed her menstrual cycle. After reducing the dose to 6 mg/day, her symptoms improved and her prolactin levels decreased. Overall, there was improvement in her psychopathology and hyperprolactinaemia. [Extracted from the article]

An 86-year-old woman developed fatal hepatitis while being treated with ceftriaxone for leukocyturia and risperidone for a psychiatric disorder. The woman presented to the hospital with prostration and food refusal, and had recently had her psychiatric medication adjusted. She experienced worsening laboratory values and was diagnosed with hepatitis secondary to ceftriaxone and risperidone. Treatment with ceftriaxone was stopped, and while there was some improvement in her condition, she ultimately passed away due to hepatitis. [Extracted from the article]

This document provides a list of drugs associated with non-serious adverse events identified in the scientific literature over the last week. The table includes the drug names, the adverse events, and the number of cases reported. Some of the drugs mentioned include Amlodipine, Apixaban, BCG, Bupivacaine, Fentanyl, Carbimazole, Cefalexin, Ceftriaxone, Vancomycin, Ciclosporin, Colchicine, Ciprofloxacin, Clonidine, Risperidone, Crizotinib, Dasatinib, Dexamethasone, Estradiol, Imiquimod, Salicylic acid, Infliximab, Ipilimumab, Nivolumab, Lenalidomide, Lidocaine, Nemolizumab, Oxaliplatin, Pembrolizumab, Risankizumab, Romosozumab, Secukinumab, Sulfur hexafluoride, Tirabrutinib, Tozinameran, and Triamcinolone. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 78-year-old man exhibited a lack of efficacy following treatment with risperidone for visual hallucinations [route not stated]. [Extracted from the article]

A man in his late 60s experienced various toxicities while undergoing antipsychotic therapy with risperidone, olanzapine, and lurasidone. These toxicities included parkinsonism, oral tardive dyskinesias, metabolic adverse effects, and neuroleptic malignant syndrome (NMS). The man also did not respond well to treatment with clomipramine and olanzapine for major depressive disorder with psychotic nihilist symptoms. The specific dosages, time to reaction onset, and outcomes were not provided, and the route and duration of treatment were also not mentioned. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn a prospective observational study of 215 patients to evaluate predefined subset of drugs and its association with QT interval prolongation, et al. patients [ages and sexs not stated] were described who developed QT interval prolongation during the treatment with azithromycin, clindamycin, escitalopram and risperidone [routes, dosages, durations of treatments to reactions onset, outcomes and indiactions not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA man [age not stated] exhibited lack of efficacy during treatment with aripiprazole and risperidone for paranoid schizophrenia. In his early 50s, he developed developed paroxysmal perceptual alterations (PPA) during treatment with flupentixol for paranoid schizophrenia [not all dosages stated and all routes not stated]. [Extracted from the article]